Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Prospective evaluation of venetoclax combined with CLAG regimen in relapsed/refractory acute myeloid leukemia: A multicenter, randomized controlled, open-lable, phase II Trial

View Full Paper
Ask AI
Bookmark
Share

Authors

YZYu ZhangSecond Military Medical University

Discussion

Loading...

Member takes

Implication

Randomized controlled trial shows venetoclax improves composite complete remission rates in relapsed/refractory AML patients, suggesting enhanced outcomes.

Key Points

  • The combination of venetoclax and CLAG regimen achieved a 75.6% composite complete remission rate in relapsed/refractory AML patients.
  • Significantly higher overall response rates of 85.4% versus 52.6% were observed with venetoclax treatment compared to the control group.
  • Trial evaluated 79 randomized patients; venetoclax+CLAG improved overall survival at one year to 80.8% against 57.4% in the control.
  • Salvage treatment implications highlight potential benefits, as adverse events were similar in both treatment groups.

Cite This Study

Yu Zhang (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e391https://doi.org/10.1182/blood-2025-1000
View Full Paper
Ask AI
Bookmark
Share